A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.
By : |
07-27-2011
|
Health and Fitness:Health and Fitness
| Total Views :
682